Newly-released Cancer Biopsy Market analysis report by Future Market Insights shows that global sales of the Cancer Biopsy Market in 2022 were held at USD 22.2 Billion. With a CAGR of 18%, the projected market growth from 2023 to 2033 is expected to be higher than the historical growth. The Tissue Biopsies type is expected to be the highest revenue-generating segment, accounting for a CAGR of nearly 19% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Cancer Biopsy Market (2023) | USD 25.5 Billion |
| Global Cancer Biopsy Market (2033) | USD 131.4 Billion |
| Global Cancer Biopsy Market CAGR (2023 to 2033) | 18% |
| USA Cancer Biopsy Market CAGR (2023 to 2033) | 21.4% |
| Key Companies Profiled | Qiagen N.V.; Illumina, Inc.; ANGLE Plc; Becton, Dickinson, and Company; Myriad Genetics; Hologic, Inc.; Biocept, Inc.; Thermo Fisher Scientific, Inc.; Danaher; F. Hoffmann-La Roche Ltd.; Lucence Diagnostics Pte. Ltd.; GRAIL, Inc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Cancer Biopsy Market industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 13.9% CAGR, wherein, countries such as the USA, United Kingdom, China, Japan, and South Korea held a significant share in the global market.
The increasing elderly populace, along with the rise in instances of cancer diagnoses, is fueling growth in the cancer clinical market. Also, the effective and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.
Some of today's prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which have been found to be less invasive and faster, are aiding the increase in popularity of the slice.
People have much higher rates of cancer nowadays not just because of medical problems like blood pressure and substance abuse, but also because of environmental causes, use of tobacco, biological irrevocable factors, and changes in lifestyle. Cancer is the second biggest cause of death worldwide as a result of contagious viral agents, chemical exposures, toxins, poor environmental factors, substance abuse, and lifestyle choices.
The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.
Principal Consultant
During the forecast period, the market in North America is projected to account for a significant share, with the USA playing a large role in regional revenue. Consequently, effective methods that the US government and its agencies have found are extensively used, permitting liquid biopsies to be developed for use in new states across the nation.
The FDA for quick-sampling practices implements regulatory strategies based on the USA. The recommendations and the approval precedents for specially generated biomarkers, companion diagnostics, and provisional categories of fit under this framework are steps toward the completion of the CLIA-related advancement of liquid biopsy regulatory channels. The incremental success of FDA approval for the Clinical Laboratory Improvement Amendment (CLIA) has included the advancement of liquid biopsy regulatory channels.
With the growing number of breast cancer patients in Asia-Pacific, increased awareness of breast cancer liquid biopsy procedures, growth in the area of in-depth research and development in breast cancer testing, and improved health-related policies as well as the adoption of breast cancer liquid biopsy, companies are seeing lucrative opportunities for their presence in the region.
Breast cancer liquid biopsy reagent kits have the highest demand and are increasingly seen as less invasive. Market growth is also being driven by manufacturers' business development efforts in emerging economies, including in Asia-Pacific, where they are attempting to achieve a higher share of the world's fugitive liquid biopsy product market.
Biotech businesses in South Korea market cancer DNA biopsy, which allows for early detection, precise treatment, and prognostic evaluation. In the future, the market is planning to depend more on genetic mutations that lead to cancer. Growth in this sector is contingent on raising the popularity of such businesses. In the future term, client interactions and fresh research are likely to fuel market expansion.
The market in the USA is expected to reach a market size of USD 57 Million by 2033. The market in the country is expected to swell at a CAGR of 21.4% from 2023 to 2033, with an absolute dollar opportunity of USD 49 Million.
The market in the United Kingdom is expected to reach a valuation of USD 4.1 Billion by 2033. Growing with a CAGR of 15.7% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of USD 3.1 Billion.
In Japan, the market is expected to grow at a CAGR of 19.4% from 2023 to 2033, reaching USD 6.2 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of USD 5.1 Billion during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tissue biopsies are still regarded as a mainstay of biopsies and are widely used in cancer diagnosis applications. The rigorous research procedures that assisted the progression of this market can be attributed to the effective testing of its products.
Advancements aimed at improving tissue biopsy processes are projected to keep the tissue biopsy segment in the lead over the next few years. Cernostics, for example, is working on an assay that can be used to diagnose cancer patients with Barrett's Esophagus.
This one-of-a-kind diagnostic test uses digitally scanned biopsy pictures to aid in the identification and quantification of changes occurring at the cellular or molecular level within a tissue. The tissue biopsies segmental market is expected to develop due to increased acceptance of this form of biopsy due to its high accuracy and low risk of harm.
According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer. Year the USA in 2020, an estimated 276,480 new instances of invasive breast cancer will be identified in women, with more than 40,000 new cases of non-invasive breast cancer.
Microscopic analysis of breast tissue is necessary to diagnose cancer or ascertain the tone and type, which is happening more due to the rise in diagnoses. Thanks to the increase in individuals with cancer, the need for needle or surgical biopsies to acquire tissue for analysis has increased, contributing to market growth.
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
Key recent developments of key players in the Cancer Biopsy Market are as follows:
Similarly, recent developments related to companies in the Cancer Biopsy Market have been tracked by the team at Future Market Insights, which are available in the full report.
The market is valued at USD 25.5 billion in 2023.
The growth potential of the cancer biopsy market is 18% CAGR through 2033.
The market is estimated to reach USD 131.4 billion by 2033.
The United States market is expected to expand at a CAGR of 21.4% through 2033.
Tissue biopsies are expected to find greater applications in cancer diagnosis.
1. Executive Summary 2. Market Overview 3. Market Risks and Trends Assessment 4. Market Background 5. Key Success Factors 6. Global Market Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 8.1. Tissue Biopsies 8.1.1. Needle Biopsies 8.1.2. Surgical Biopsies 8.2. Liquid Biopsies 8.3. Other Types 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 9.1. Instruments 9.2. Kits and Consumables 9.3. Services 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 10.1. Software 10.2. Services 10.3. Cervical Cancers 10.4. Training and Education Services 10.5. Prostate Cancers 10.6. Blood Cancers 10.7. Skin Cancers 10.8. Kidney Cancers 10.9. Liver Cancers 10.10. Pancreatic Cancers 10.11. Ovarian Cancers 10.12. Other Applications 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. Asia Pacific 11.5. Middle East and Africa (MEA) 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17. Key Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. Qiagen N.V. 19.2. Illumina, Inc. 19.3. ANGLE Plc 19.4. Becton, Dickinson, and Company 19.5. Myriad Genetics 19.6. Hologic, Inc. 19.7. Biocept, Inc. 19.8. Thermo Fisher Scientific, Inc. 19.9. Danaher 19.10. F. Hoffmann-La Roche Ltd. 19.11. Lucence Diagnostics Pte. Ltd. 19.12. GRAIL, Inc. 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Biopsy Market
